OBJECTIVE Treatment with dimethyl fumarate (DMF) leads to lymphopenia and infectious complications in a subset of patients with multiple sclerosis (MS). Here, we aimed to reveal immune markers of DMF-associated… Click to show full abstract
OBJECTIVE Treatment with dimethyl fumarate (DMF) leads to lymphopenia and infectious complications in a subset of patients with multiple sclerosis (MS). Here, we aimed to reveal immune markers of DMF-associated lymphopenia. METHODS This prospective observational study longitudinally assessed 31 individuals with MS by single-cell mass cytometry before, and after 12 and 48 weeks of DMF therapy. RESULTS Employing a neural network-based representation learning approach, we identified a CCR4-expressing T helper cell population negatively associated with relevant lymphopenia. INTERPRETATION CCR4-expressing T helper cells represent a candidate prognostic biomarker for the development of relevant lymphopenia in patients undergoing DMF treatment. This article is protected by copyright. All rights reserved.
               
Click one of the above tabs to view related content.